Photos: 

Some evaluation reports are public and can be downloaded from this website, while others are restricted to MSF users and can only be accessed via Tukul. This limitation is mainly due to the sensitive nature of the operational contexts and the resulting content. However, there are internal discussions about making all evaluation reports publicly searchable. If you are an MSF association member, reports are made available on various associate platforms such as www.insideOCB.com.

Country/Region

This document describes the project Lessons identified at the end of the market entry planning phase for MSF in Finland. It summarises the successes and challenges encountered during the project, lists the learning themes arising from these successes and challenges, and includes a set of lessons derived from an analysis of these learning points. The Annex contains a proposed (brief) framework with criteria and pre-requisites for a successful Market Entry Plan in MSF based on this experience. NOTE: This is not an evaluation and therefore there is no ambition for independent judgement.

This Retrospect was facilitated by the Stockholm Evaluation Unit on behalf of the Project Team. The report has been prepared by Timothy McCann.
30/10/2017

The evaluation analysed MSF intervention strategies of the TB project in the Penal sector of Kyrgyzstan by reviewing relevance, effectiveness and continuity. It assessed current challenges and shortcomings of the intervention in order to recommend new techniques and approaches for the year 2011 and beyond.

Gill Bradbury, Walli Wernhart, and Dr. A.Jamil Faqirzai
08/10/2010

The Bosnia programme was one of the largest programmes MSF has implemented so far, and it was the first major operation MSF executed in an European environment. There was a widely shared view that the programme had gone “out of control”. As a result, many within MSF considered drug distribution in general as being beyond the scope of MSF. The dominance of drug distribution in the programme was perceived to be in contradiction with the medical identity of MSF.

Van de Putte, B. and Maslesa, L.
01/04/1998